Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Cholinesterase inhibitors remain the long-standing pharmacologic standard in Alzheimer's disease, yet their measured effect on cognition is modest and does not alter the underlying course of neurodegeneration. The distinction between temporarily supporting neurotransmission and preserving neuronal tissue defines both the ceiling of these drugs and the case for addressing modifiable risk decades earlier.
ZNF865 (BLST), a previously uncharacterized zinc finger protein, has been identified as a regulator of genomic stability and cellular senescence in the intervertebral disc. Its expression declines with age and degeneration in human and mouse discs, and experimental suppression drives senescence, DNA damage, disc degeneration, and pain behavior in rodents, while restoration reverses senescent features and restores chromatin accessibility toward a healthy state. The finding links a discrete molecular control point to both tissue aging and the clinical experience of pain.
Deep Longevity will launch Accrua, a US telehealth platform that anchors prescriptions for GLP-1 agonists, peptides and hormone therapy to a blood-based biological age score rather than symptoms alone, with quarterly re-testing. The underlying model draws on a cohort of roughly 2,600 adults followed for 9.2 years, in which each year of gap between biological and chronological age corresponded to a 15% increase in mortality risk. Predictive validity is not the same as treatment utility, and no outcome data yet show that prescribing guided by the score improves results.
Genentech has acquired exclusive worldwide rights to Alector's AL050, an engineered glucocerebrosidase (GCase) enzyme replacement therapy for Parkinson's disease, for $100 million upfront and up to $1.17 billion in milestones. The candidate targets deficient lysosomal lipid clearance in neurons, a mechanism strongly associated with GBA1 mutations, and is paired with a proprietary carrier designed to cross the blood-brain barrier. AL050 has not yet entered clinical trials, and no human or delivery data were disclosed.
Tiny Health raised a $33m Series B to expand shotgun metagenomic microbiome testing from infants to adults, with adult samples now exceeding pediatric volume. Its strongest evidence is a 2025 randomized controlled trial reporting an 83% reduction in the odds of infant eczema following targeted microbiome intervention. The company acknowledges there is no universal definition of a healthy adult microbiome and that its new longevity-oriented scores have not yet been shown to predict health outcomes.
Cognition Therapeutics will meet the FDA on 20 October to finalize how success is measured in a planned Phase 3 trial of zervimesine (CT1812) for dementia with Lewy bodies, with psychosis — hallucinations and delusions — proposed as the primary endpoint. The agency has previously indicated psychosis could serve both as an approvable outcome and as a marker of disease progression. In the earlier Phase 2 SHIMMER study, the company reported an 89% slowing of progression in hallucinations and delusions versus placebo on the neuropsychiatric inventory.
A conference at the European Parliament on October 1, hosted by MEP Valentina Palmisano and organized by the Longevity Policies Association and International Longevity Alliance, pressed for geroscience and preventive medicine to be treated as a distinct EU health policy field rather than a subset of pension and social care planning. Speakers from the Commission, clinical practice and research argued that biomedical advances in aging biology stall without a framework to carry them into population health. The practical test is whether the effort secures funding in FP10 and regulatory language, not whether it generates further discussion.
In SAMP8 mice, a model of accelerated aging, males and females followed distinct trajectories of hippocampal neurogenesis despite comparable cognitive performance at six months. The diterpenoid compound ER272 was associated with improved cognition and preservation of neurogenic parameters in males only, with limited effect in females. The findings indicate that sex modifies both the biology of brain aging and the response to interventions aimed at slowing it.
Jupiter Neurosciences has dosed the first patient in RESET, a Phase 2a randomized, double-blind, placebo-controlled trial of JOTROL — a micellar trans-resveratrol formulation — in approximately 30 Parkinson's disease patients over 12 weeks. Primary endpoints are safety, tolerability and pharmacokinetics, with exploratory biomarkers covering energy metabolism and inflammation. Phase 1 data reportedly showed increased systemic exposure and measurable cerebrospinal fluid concentrations without serious adverse events.
AgelessRx has released a prescription copper peptide (GHK-Cu) cream in two compounded strengths, 0.5% and 3%, intended to support skin repair processes that decline with age. Each prescription requires review by a licensed provider, and the company reports 99.8% purity alongside microbial and endotoxin testing; compounded formulations are not FDA-approved. The launch places a well-characterized endogenous peptide into a clinician-supervised dosing model rather than an over-the-counter cosmetic one.
In 21,446–29,713 UK Biobank participants, higher birthweight was associated with younger proteomic age across 11 organ systems, with the strongest signals in intestine, esophagus, and stomach. Breastfeeding showed organ-specific associations — slower intestinal and adrenal aging but modestly faster thyroid aging — and combined exposure produced the most favorable multi-organ profiles. Allostatic load mediated up to 35.3% of the birthweight association, indicating that cumulative physiological burden in adulthood carries part of the early-life signal forward.
Measurements of autophagy flux in human tissue show that the cellular recycling process is not uniformly diminished with age but remodeled in patterns that differ by sex and by cell type. Lower flux in older adults corresponded with reduced physical function, linking a core quality-control mechanism to measurable performance decline.